Clinical Trials

Processa Pharmaceuticals acquires Vidya Therapeutics and its key asset, VT-7208, backed by a $200M financing that radically overhauls the company's strategy.

A new study suggests A2-protein infant formula may boost growth, a potential game-changer. But with preliminary data, experts urge caution.

Oak Hill Bio is betting on a therapy shelved by a pharma giant. Its new trial for Angelman syndrome tests a disruptive model for rare disease innovation.

An Australian biotech's breakthrough study on fucoidan, a seaweed compound, offers a safe, clinically-proven new option for men suffering from BPH.

A breakthrough BCI not only restores movement and sensation but promotes lasting change. Joyce Watson analyzes how Neuvotion is turning science into a business.

Small biotech Veru Inc. is betting its future on improving blockbuster weight-loss drugs, targeting the hidden cost of muscle loss in a billion-dollar market.

Internal data showing an 82% overlap between HPV and STI cases fuels Seegene's push for a single, comprehensive test, challenging decades of siloed screening.

With a new CMO and fresh funding, Spero Therapeutics is betting big on its immunology asset SP001. Can Dr. Zack guide it to success in a competitive field?

Following a strategic merger and a $200M financing round, Yarrow Bioscience is advancing a novel drug for autoimmune thyroid disease. But can it disrupt a market dominated by incumbents?

With the hire of Abecma veteran Dr. Steven Bernstein, Liberate Bio signals its readiness to take its 'off-the-shelf' CAR-M therapy into the clinic.

Promising early data for BBT001 suggests a potent combination of rapid relief and quarterly dosing, but can the biotech startup navigate the long road from pilot to production?

With its $2.2B acquisition of Forte, argenx adds a first-in-class antibody, FB102, expanding its Vision 2030 strategy to redefine autoimmune care.

New trial data shows an incision-free therapy preserves patient quality of life, challenging the long-held dominance of robotic surgery in prostate cancer.

A positive EMA opinion for Minoryx's NEZGLYAL offers the first-ever drug therapy for a fatal childhood disease, highlighting a key regulatory pathway.

Radiopharm Theranostics secures crucial funding for its promising oncology pipeline, but a sharp stock drop reveals deep investor concerns about dilution.

Samsung Epis Holdings reports solid growth driven by its biosimilar portfolio, but the real story is its strategic pivot to next-gen cancer drugs and global expansion.

Ipsen's BOLD trial for biliary atresia failed, a blow to families. But in the data from this setback lies a critical roadmap for future research.

Taiwan's Jyong Biotech touts a global licensing strategy for its BPH drug, but a closer look reveals significant clinical setbacks and financial pressures.

A Korean biotech is betting big on the U.S. market with its new GERD drug. A deal with manufacturer Bora Pharmaceuticals is the first step. Is it enough?